nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—PTGER2—myometrium—ovarian cancer	0.0169	0.0497	CbGeAlD
Alprostadil—PTGER2—uterine cervix—ovarian cancer	0.0131	0.0386	CbGeAlD
Alprostadil—PTGER2—decidua—ovarian cancer	0.0125	0.0368	CbGeAlD
Alprostadil—PTGER2—endometrium—ovarian cancer	0.0119	0.035	CbGeAlD
Alprostadil—PTGER2—uterus—ovarian cancer	0.0109	0.0322	CbGeAlD
Alprostadil—PTGER2—female reproductive system—ovarian cancer	0.00983	0.029	CbGeAlD
Alprostadil—PTGER1—female reproductive system—ovarian cancer	0.00932	0.0274	CbGeAlD
Alprostadil—PTGER2—bone marrow—ovarian cancer	0.00928	0.0273	CbGeAlD
Alprostadil—PTGER2—female gonad—ovarian cancer	0.00894	0.0263	CbGeAlD
Alprostadil—PTGER2—vagina—ovarian cancer	0.00889	0.0262	CbGeAlD
Alprostadil—SLCO3A1—myometrium—ovarian cancer	0.00871	0.0257	CbGeAlD
Alprostadil—SLCO2A1—myometrium—ovarian cancer	0.00863	0.0254	CbGeAlD
Alprostadil—PTGER1—female gonad—ovarian cancer	0.00848	0.025	CbGeAlD
Alprostadil—PTGER2—testis—ovarian cancer	0.00793	0.0234	CbGeAlD
Alprostadil—PTGIR—epithelium—ovarian cancer	0.00775	0.0228	CbGeAlD
Alprostadil—SLCO3A1—uterine cervix—ovarian cancer	0.00678	0.02	CbGeAlD
Alprostadil—SLCO2A1—epithelium—ovarian cancer	0.00677	0.02	CbGeAlD
Alprostadil—SLCO2A1—uterine cervix—ovarian cancer	0.00672	0.0198	CbGeAlD
Alprostadil—PTGIR—gonad—ovarian cancer	0.00645	0.019	CbGeAlD
Alprostadil—SLCO2A1—decidua—ovarian cancer	0.0064	0.0188	CbGeAlD
Alprostadil—ABCC5—uterine cervix—ovarian cancer	0.00614	0.0181	CbGeAlD
Alprostadil—SLCO2A1—endometrium—ovarian cancer	0.00607	0.0179	CbGeAlD
Alprostadil—ABCC5—decidua—ovarian cancer	0.00585	0.0172	CbGeAlD
Alprostadil—PTGIR—female reproductive system—ovarian cancer	0.00576	0.017	CbGeAlD
Alprostadil—PTGER2—lymph node—ovarian cancer	0.00575	0.0169	CbGeAlD
Alprostadil—SLCO3A1—gonad—ovarian cancer	0.00569	0.0168	CbGeAlD
Alprostadil—SLCO2A1—uterus—ovarian cancer	0.0056	0.0165	CbGeAlD
Alprostadil—PTGIR—female gonad—ovarian cancer	0.00524	0.0154	CbGeAlD
Alprostadil—SLCO3A1—female reproductive system—ovarian cancer	0.00508	0.015	CbGeAlD
Alprostadil—SLCO2A1—female reproductive system—ovarian cancer	0.00503	0.0148	CbGeAlD
Alprostadil—PTGIR—testis—ovarian cancer	0.00465	0.0137	CbGeAlD
Alprostadil—SLCO3A1—female gonad—ovarian cancer	0.00462	0.0136	CbGeAlD
Alprostadil—SLCO3A1—vagina—ovarian cancer	0.00459	0.0135	CbGeAlD
Alprostadil—SLCO2B1—decidua—ovarian cancer	0.00458	0.0135	CbGeAlD
Alprostadil—SLCO2A1—female gonad—ovarian cancer	0.00458	0.0135	CbGeAlD
Alprostadil—SLCO2A1—vagina—ovarian cancer	0.00455	0.0134	CbGeAlD
Alprostadil—ABCC5—bone marrow—ovarian cancer	0.00434	0.0128	CbGeAlD
Alprostadil—ABCC5—female gonad—ovarian cancer	0.00419	0.0123	CbGeAlD
Alprostadil—ABCC5—vagina—ovarian cancer	0.00416	0.0123	CbGeAlD
Alprostadil—SLCO3A1—testis—ovarian cancer	0.0041	0.0121	CbGeAlD
Alprostadil—SLCO2A1—testis—ovarian cancer	0.00406	0.012	CbGeAlD
Alprostadil—SLCO2B1—uterus—ovarian cancer	0.00401	0.0118	CbGeAlD
Alprostadil—ABCC5—testis—ovarian cancer	0.00371	0.0109	CbGeAlD
Alprostadil—SLCO2B1—female reproductive system—ovarian cancer	0.0036	0.0106	CbGeAlD
Alprostadil—ABCC4—uterus—ovarian cancer	0.00355	0.0105	CbGeAlD
Alprostadil—PTGIR—lymph node—ovarian cancer	0.00337	0.00992	CbGeAlD
Alprostadil—SLCO2B1—female gonad—ovarian cancer	0.00328	0.00965	CbGeAlD
Alprostadil—ABCC4—female reproductive system—ovarian cancer	0.00319	0.0094	CbGeAlD
Alprostadil—ABCC4—bone marrow—ovarian cancer	0.00301	0.00887	CbGeAlD
Alprostadil—SLCO3A1—lymph node—ovarian cancer	0.00297	0.00875	CbGeAlD
Alprostadil—SLCO2A1—lymph node—ovarian cancer	0.00294	0.00867	CbGeAlD
Alprostadil—SLCO2B1—testis—ovarian cancer	0.00291	0.00856	CbGeAlD
Alprostadil—ABCC4—female gonad—ovarian cancer	0.0029	0.00855	CbGeAlD
Alprostadil—ABCC5—lymph node—ovarian cancer	0.00269	0.00793	CbGeAlD
Alprostadil—ABCC4—testis—ovarian cancer	0.00257	0.00758	CbGeAlD
Alprostadil—SLCO2B1—lymph node—ovarian cancer	0.00211	0.00621	CbGeAlD
Alprostadil—ABCC4—lymph node—ovarian cancer	0.00187	0.0055	CbGeAlD
Alprostadil—Cramps of lower extremities—Epirubicin—ovarian cancer	0.000878	0.0018	CcSEcCtD
Alprostadil—Sinusitis—Paclitaxel—ovarian cancer	0.000878	0.00179	CcSEcCtD
Alprostadil—Hyperkalaemia—Doxorubicin—ovarian cancer	0.000869	0.00178	CcSEcCtD
Alprostadil—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000869	0.00178	CcSEcCtD
Alprostadil—Pain—Melphalan—ovarian cancer	0.000868	0.00178	CcSEcCtD
Alprostadil—Tachycardia—Vinorelbine—ovarian cancer	0.000866	0.00177	CcSEcCtD
Alprostadil—Ecchymosis—Epirubicin—ovarian cancer	0.000865	0.00177	CcSEcCtD
Alprostadil—Skin disorder—Vinorelbine—ovarian cancer	0.000862	0.00176	CcSEcCtD
Alprostadil—Influenza like illness—Doxorubicin—ovarian cancer	0.000859	0.00176	CcSEcCtD
Alprostadil—Bradycardia—Paclitaxel—ovarian cancer	0.000855	0.00175	CcSEcCtD
Alprostadil—Feeling abnormal—Topotecan—ovarian cancer	0.000855	0.00175	CcSEcCtD
Alprostadil—Haemoglobin—Paclitaxel—ovarian cancer	0.000844	0.00173	CcSEcCtD
Alprostadil—Rhinitis—Paclitaxel—ovarian cancer	0.000842	0.00172	CcSEcCtD
Alprostadil—Haemorrhage—Paclitaxel—ovarian cancer	0.00084	0.00172	CcSEcCtD
Alprostadil—Asthenia—Chlorambucil—ovarian cancer	0.000836	0.00171	CcSEcCtD
Alprostadil—Hypoaesthesia—Paclitaxel—ovarian cancer	0.000836	0.00171	CcSEcCtD
Alprostadil—Abnormal vision—Epirubicin—ovarian cancer	0.000834	0.00171	CcSEcCtD
Alprostadil—Pharyngitis—Paclitaxel—ovarian cancer	0.000834	0.0017	CcSEcCtD
Alprostadil—Sepsis—Epirubicin—ovarian cancer	0.00083	0.0017	CcSEcCtD
Alprostadil—Hypotension—Vinorelbine—ovarian cancer	0.000829	0.0017	CcSEcCtD
Alprostadil—Pruritus—Chlorambucil—ovarian cancer	0.000824	0.00169	CcSEcCtD
Alprostadil—Urethral disorder—Paclitaxel—ovarian cancer	0.000823	0.00168	CcSEcCtD
Alprostadil—Body temperature increased—Topotecan—ovarian cancer	0.00082	0.00168	CcSEcCtD
Alprostadil—Abdominal pain—Topotecan—ovarian cancer	0.00082	0.00168	CcSEcCtD
Alprostadil—Cramps of lower extremities—Doxorubicin—ovarian cancer	0.000813	0.00166	CcSEcCtD
Alprostadil—Visual impairment—Paclitaxel—ovarian cancer	0.000809	0.00165	CcSEcCtD
Alprostadil—Ecchymosis—Doxorubicin—ovarian cancer	0.0008	0.00164	CcSEcCtD
Alprostadil—Diabetes mellitus—Epirubicin—ovarian cancer	0.000798	0.00163	CcSEcCtD
Alprostadil—Diarrhoea—Chlorambucil—ovarian cancer	0.000797	0.00163	CcSEcCtD
Alprostadil—Acute coronary syndrome—Docetaxel—ovarian cancer	0.000782	0.0016	CcSEcCtD
Alprostadil—Renal failure—Docetaxel—ovarian cancer	0.00078	0.00159	CcSEcCtD
Alprostadil—Flushing—Paclitaxel—ovarian cancer	0.00078	0.00159	CcSEcCtD
Alprostadil—Myocardial infarction—Docetaxel—ovarian cancer	0.000777	0.00159	CcSEcCtD
Alprostadil—Abnormal vision—Doxorubicin—ovarian cancer	0.000772	0.00158	CcSEcCtD
Alprostadil—Sepsis—Doxorubicin—ovarian cancer	0.000768	0.00157	CcSEcCtD
Alprostadil—Cardiac failure congestive—Epirubicin—ovarian cancer	0.000765	0.00156	CcSEcCtD
Alprostadil—Pain—Vinorelbine—ovarian cancer	0.000759	0.00155	CcSEcCtD
Alprostadil—Asthenia—Topotecan—ovarian cancer	0.000744	0.00152	CcSEcCtD
Alprostadil—Diabetes mellitus—Doxorubicin—ovarian cancer	0.000738	0.00151	CcSEcCtD
Alprostadil—Pruritus—Topotecan—ovarian cancer	0.000734	0.0015	CcSEcCtD
Alprostadil—Erythema—Paclitaxel—ovarian cancer	0.000731	0.00149	CcSEcCtD
Alprostadil—Feeling abnormal—Vinorelbine—ovarian cancer	0.000731	0.00149	CcSEcCtD
Alprostadil—Asthenia—Melphalan—ovarian cancer	0.000729	0.00149	CcSEcCtD
Alprostadil—Pruritus—Melphalan—ovarian cancer	0.000718	0.00147	CcSEcCtD
Alprostadil—Haemoglobin—Docetaxel—ovarian cancer	0.000716	0.00146	CcSEcCtD
Alprostadil—Rhinitis—Docetaxel—ovarian cancer	0.000714	0.00146	CcSEcCtD
Alprostadil—Haemorrhage—Docetaxel—ovarian cancer	0.000712	0.00146	CcSEcCtD
Alprostadil—Hypoglycaemia—Epirubicin—ovarian cancer	0.000711	0.00145	CcSEcCtD
Alprostadil—Nervousness—Paclitaxel—ovarian cancer	0.00071	0.00145	CcSEcCtD
Alprostadil—Diarrhoea—Topotecan—ovarian cancer	0.00071	0.00145	CcSEcCtD
Alprostadil—Hypoaesthesia—Docetaxel—ovarian cancer	0.000708	0.00145	CcSEcCtD
Alprostadil—Lethargy—Epirubicin—ovarian cancer	0.000708	0.00145	CcSEcCtD
Alprostadil—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.000708	0.00145	CcSEcCtD
Alprostadil—Back pain—Paclitaxel—ovarian cancer	0.000707	0.00145	CcSEcCtD
Alprostadil—Pharyngitis—Docetaxel—ovarian cancer	0.000707	0.00144	CcSEcCtD
Alprostadil—Muscle spasms—Paclitaxel—ovarian cancer	0.000703	0.00144	CcSEcCtD
Alprostadil—Abdominal pain—Vinorelbine—ovarian cancer	0.000701	0.00143	CcSEcCtD
Alprostadil—Body temperature increased—Vinorelbine—ovarian cancer	0.000701	0.00143	CcSEcCtD
Alprostadil—Urethral disorder—Docetaxel—ovarian cancer	0.000698	0.00143	CcSEcCtD
Alprostadil—Diarrhoea—Melphalan—ovarian cancer	0.000695	0.00142	CcSEcCtD
Alprostadil—Pain in extremity—Epirubicin—ovarian cancer	0.000694	0.00142	CcSEcCtD
Alprostadil—Nausea—Chlorambucil—ovarian cancer	0.000692	0.00141	CcSEcCtD
Alprostadil—Visual impairment—Docetaxel—ovarian cancer	0.000686	0.0014	CcSEcCtD
Alprostadil—Dizziness—Topotecan—ovarian cancer	0.000686	0.0014	CcSEcCtD
Alprostadil—Anaemia—Paclitaxel—ovarian cancer	0.000676	0.00138	CcSEcCtD
Alprostadil—Flushing—Docetaxel—ovarian cancer	0.000661	0.00135	CcSEcCtD
Alprostadil—Cardiac arrest—Epirubicin—ovarian cancer	0.00066	0.00135	CcSEcCtD
Alprostadil—Hypoglycaemia—Doxorubicin—ovarian cancer	0.000658	0.00135	CcSEcCtD
Alprostadil—Syncope—Paclitaxel—ovarian cancer	0.000656	0.00134	CcSEcCtD
Alprostadil—Lethargy—Doxorubicin—ovarian cancer	0.000655	0.00134	CcSEcCtD
Alprostadil—Rash—Topotecan—ovarian cancer	0.000654	0.00134	CcSEcCtD
Alprostadil—Dermatitis—Topotecan—ovarian cancer	0.000653	0.00134	CcSEcCtD
Alprostadil—Blood creatinine increased—Epirubicin—ovarian cancer	0.00065	0.00133	CcSEcCtD
Alprostadil—Headache—Topotecan—ovarian cancer	0.00065	0.00133	CcSEcCtD
Alprostadil—Loss of consciousness—Paclitaxel—ovarian cancer	0.000643	0.00131	CcSEcCtD
Alprostadil—Pain in extremity—Doxorubicin—ovarian cancer	0.000642	0.00131	CcSEcCtD
Alprostadil—Rash—Melphalan—ovarian cancer	0.00064	0.00131	CcSEcCtD
Alprostadil—Dermatitis—Melphalan—ovarian cancer	0.00064	0.00131	CcSEcCtD
Alprostadil—Cough—Paclitaxel—ovarian cancer	0.000638	0.0013	CcSEcCtD
Alprostadil—Asthenia—Vinorelbine—ovarian cancer	0.000637	0.0013	CcSEcCtD
Alprostadil—Convulsion—Paclitaxel—ovarian cancer	0.000634	0.0013	CcSEcCtD
Alprostadil—Hypokalaemia—Epirubicin—ovarian cancer	0.000632	0.00129	CcSEcCtD
Alprostadil—Hypertension—Paclitaxel—ovarian cancer	0.000631	0.00129	CcSEcCtD
Alprostadil—Pruritus—Vinorelbine—ovarian cancer	0.000628	0.00128	CcSEcCtD
Alprostadil—Erythema—Docetaxel—ovarian cancer	0.00062	0.00127	CcSEcCtD
Alprostadil—Nausea—Topotecan—ovarian cancer	0.000616	0.00126	CcSEcCtD
Alprostadil—Discomfort—Paclitaxel—ovarian cancer	0.000615	0.00126	CcSEcCtD
Alprostadil—Cardiac arrest—Doxorubicin—ovarian cancer	0.000611	0.00125	CcSEcCtD
Alprostadil—Dry mouth—Paclitaxel—ovarian cancer	0.000609	0.00124	CcSEcCtD
Alprostadil—Diarrhoea—Vinorelbine—ovarian cancer	0.000607	0.00124	CcSEcCtD
Alprostadil—Nausea—Melphalan—ovarian cancer	0.000603	0.00123	CcSEcCtD
Alprostadil—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000602	0.00123	CcSEcCtD
Alprostadil—Influenza—Epirubicin—ovarian cancer	0.0006	0.00123	CcSEcCtD
Alprostadil—Back pain—Docetaxel—ovarian cancer	0.000599	0.00123	CcSEcCtD
Alprostadil—Oedema—Paclitaxel—ovarian cancer	0.000597	0.00122	CcSEcCtD
Alprostadil—Muscle spasms—Docetaxel—ovarian cancer	0.000596	0.00122	CcSEcCtD
Alprostadil—Infection—Paclitaxel—ovarian cancer	0.000593	0.00121	CcSEcCtD
Alprostadil—Shock—Paclitaxel—ovarian cancer	0.000587	0.0012	CcSEcCtD
Alprostadil—Dizziness—Vinorelbine—ovarian cancer	0.000587	0.0012	CcSEcCtD
Alprostadil—Hypokalaemia—Doxorubicin—ovarian cancer	0.000585	0.0012	CcSEcCtD
Alprostadil—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000584	0.00119	CcSEcCtD
Alprostadil—Tachycardia—Paclitaxel—ovarian cancer	0.000582	0.00119	CcSEcCtD
Alprostadil—Skin disorder—Paclitaxel—ovarian cancer	0.00058	0.00119	CcSEcCtD
Alprostadil—Bronchitis—Epirubicin—ovarian cancer	0.000577	0.00118	CcSEcCtD
Alprostadil—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000577	0.00118	CcSEcCtD
Alprostadil—Anaemia—Docetaxel—ovarian cancer	0.000573	0.00117	CcSEcCtD
Alprostadil—Rash—Vinorelbine—ovarian cancer	0.000559	0.00114	CcSEcCtD
Alprostadil—Dermatitis—Vinorelbine—ovarian cancer	0.000559	0.00114	CcSEcCtD
Alprostadil—Hypotension—Paclitaxel—ovarian cancer	0.000558	0.00114	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000558	0.00114	CcSEcCtD
Alprostadil—Headache—Vinorelbine—ovarian cancer	0.000556	0.00114	CcSEcCtD
Alprostadil—Syncope—Docetaxel—ovarian cancer	0.000556	0.00114	CcSEcCtD
Alprostadil—Influenza—Doxorubicin—ovarian cancer	0.000555	0.00113	CcSEcCtD
Alprostadil—Pollakiuria—Epirubicin—ovarian cancer	0.000554	0.00113	CcSEcCtD
Alprostadil—Loss of consciousness—Docetaxel—ovarian cancer	0.000545	0.00111	CcSEcCtD
Alprostadil—Hyperglycaemia—Epirubicin—ovarian cancer	0.000541	0.00111	CcSEcCtD
Alprostadil—Cough—Docetaxel—ovarian cancer	0.000541	0.00111	CcSEcCtD
Alprostadil—Convulsion—Docetaxel—ovarian cancer	0.000537	0.0011	CcSEcCtD
Alprostadil—Hypertension—Docetaxel—ovarian cancer	0.000535	0.00109	CcSEcCtD
Alprostadil—Bronchitis—Doxorubicin—ovarian cancer	0.000534	0.00109	CcSEcCtD
Alprostadil—Nausea—Vinorelbine—ovarian cancer	0.000527	0.00108	CcSEcCtD
Alprostadil—Renal failure—Epirubicin—ovarian cancer	0.000526	0.00108	CcSEcCtD
Alprostadil—Dyspepsia—Paclitaxel—ovarian cancer	0.000525	0.00107	CcSEcCtD
Alprostadil—Urinary tract infection—Epirubicin—ovarian cancer	0.00052	0.00106	CcSEcCtD
Alprostadil—Dry mouth—Docetaxel—ovarian cancer	0.000516	0.00106	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000516	0.00105	CcSEcCtD
Alprostadil—Pollakiuria—Doxorubicin—ovarian cancer	0.000513	0.00105	CcSEcCtD
Alprostadil—Pain—Paclitaxel—ovarian cancer	0.00051	0.00104	CcSEcCtD
Alprostadil—Haematuria—Epirubicin—ovarian cancer	0.00051	0.00104	CcSEcCtD
Alprostadil—Oedema—Docetaxel—ovarian cancer	0.000506	0.00103	CcSEcCtD
Alprostadil—Infection—Docetaxel—ovarian cancer	0.000502	0.00103	CcSEcCtD
Alprostadil—Sinusitis—Epirubicin—ovarian cancer	0.000502	0.00103	CcSEcCtD
Alprostadil—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000501	0.00102	CcSEcCtD
Alprostadil—Shock—Docetaxel—ovarian cancer	0.000498	0.00102	CcSEcCtD
Alprostadil—Thrombocytopenia—Docetaxel—ovarian cancer	0.000495	0.00101	CcSEcCtD
Alprostadil—Tachycardia—Docetaxel—ovarian cancer	0.000494	0.00101	CcSEcCtD
Alprostadil—Feeling abnormal—Paclitaxel—ovarian cancer	0.000492	0.00101	CcSEcCtD
Alprostadil—Skin disorder—Docetaxel—ovarian cancer	0.000491	0.001	CcSEcCtD
Alprostadil—Bradycardia—Epirubicin—ovarian cancer	0.000489	0.001	CcSEcCtD
Alprostadil—Renal failure—Doxorubicin—ovarian cancer	0.000487	0.000995	CcSEcCtD
Alprostadil—Haemoglobin—Epirubicin—ovarian cancer	0.000483	0.000987	CcSEcCtD
Alprostadil—Rhinitis—Epirubicin—ovarian cancer	0.000481	0.000984	CcSEcCtD
Alprostadil—Urinary tract infection—Doxorubicin—ovarian cancer	0.000481	0.000984	CcSEcCtD
Alprostadil—Haemorrhage—Epirubicin—ovarian cancer	0.00048	0.000982	CcSEcCtD
Alprostadil—Hypoaesthesia—Epirubicin—ovarian cancer	0.000478	0.000977	CcSEcCtD
Alprostadil—Pharyngitis—Epirubicin—ovarian cancer	0.000477	0.000974	CcSEcCtD
Alprostadil—Hypotension—Docetaxel—ovarian cancer	0.000473	0.000966	CcSEcCtD
Alprostadil—Haematuria—Doxorubicin—ovarian cancer	0.000472	0.000965	CcSEcCtD
Alprostadil—Abdominal pain—Paclitaxel—ovarian cancer	0.000472	0.000965	CcSEcCtD
Alprostadil—Body temperature increased—Paclitaxel—ovarian cancer	0.000472	0.000965	CcSEcCtD
Alprostadil—Urethral disorder—Epirubicin—ovarian cancer	0.000471	0.000962	CcSEcCtD
Alprostadil—Sinusitis—Doxorubicin—ovarian cancer	0.000464	0.000949	CcSEcCtD
Alprostadil—Visual impairment—Epirubicin—ovarian cancer	0.000463	0.000946	CcSEcCtD
Alprostadil—Bradycardia—Doxorubicin—ovarian cancer	0.000452	0.000925	CcSEcCtD
Alprostadil—Haemoglobin—Doxorubicin—ovarian cancer	0.000447	0.000913	CcSEcCtD
Alprostadil—Flushing—Epirubicin—ovarian cancer	0.000446	0.000911	CcSEcCtD
Alprostadil—Rhinitis—Doxorubicin—ovarian cancer	0.000445	0.000911	CcSEcCtD
Alprostadil—Dyspepsia—Docetaxel—ovarian cancer	0.000445	0.00091	CcSEcCtD
Alprostadil—Haemorrhage—Doxorubicin—ovarian cancer	0.000444	0.000908	CcSEcCtD
Alprostadil—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000442	0.000904	CcSEcCtD
Alprostadil—Pharyngitis—Doxorubicin—ovarian cancer	0.000441	0.000902	CcSEcCtD
Alprostadil—Urethral disorder—Doxorubicin—ovarian cancer	0.000436	0.000891	CcSEcCtD
Alprostadil—Pain—Docetaxel—ovarian cancer	0.000433	0.000884	CcSEcCtD
Alprostadil—Visual impairment—Doxorubicin—ovarian cancer	0.000428	0.000875	CcSEcCtD
Alprostadil—Asthenia—Paclitaxel—ovarian cancer	0.000428	0.000875	CcSEcCtD
Alprostadil—Pruritus—Paclitaxel—ovarian cancer	0.000422	0.000863	CcSEcCtD
Alprostadil—Erythema—Epirubicin—ovarian cancer	0.000418	0.000855	CcSEcCtD
Alprostadil—Feeling abnormal—Docetaxel—ovarian cancer	0.000417	0.000852	CcSEcCtD
Alprostadil—Flushing—Doxorubicin—ovarian cancer	0.000412	0.000843	CcSEcCtD
Alprostadil—Diarrhoea—Paclitaxel—ovarian cancer	0.000408	0.000835	CcSEcCtD
Alprostadil—Nervousness—Epirubicin—ovarian cancer	0.000406	0.00083	CcSEcCtD
Alprostadil—Back pain—Epirubicin—ovarian cancer	0.000404	0.000827	CcSEcCtD
Alprostadil—Muscle spasms—Epirubicin—ovarian cancer	0.000402	0.000822	CcSEcCtD
Alprostadil—Body temperature increased—Docetaxel—ovarian cancer	0.0004	0.000818	CcSEcCtD
Alprostadil—Abdominal pain—Docetaxel—ovarian cancer	0.0004	0.000818	CcSEcCtD
Alprostadil—Dizziness—Paclitaxel—ovarian cancer	0.000395	0.000807	CcSEcCtD
Alprostadil—Erythema—Doxorubicin—ovarian cancer	0.000387	0.000791	CcSEcCtD
Alprostadil—Anaemia—Epirubicin—ovarian cancer	0.000386	0.00079	CcSEcCtD
Alprostadil—Rash—Paclitaxel—ovarian cancer	0.000376	0.000769	CcSEcCtD
Alprostadil—Dermatitis—Paclitaxel—ovarian cancer	0.000376	0.000769	CcSEcCtD
Alprostadil—Nervousness—Doxorubicin—ovarian cancer	0.000376	0.000768	CcSEcCtD
Alprostadil—Syncope—Epirubicin—ovarian cancer	0.000375	0.000766	CcSEcCtD
Alprostadil—Back pain—Doxorubicin—ovarian cancer	0.000374	0.000765	CcSEcCtD
Alprostadil—Headache—Paclitaxel—ovarian cancer	0.000374	0.000764	CcSEcCtD
Alprostadil—Muscle spasms—Doxorubicin—ovarian cancer	0.000372	0.00076	CcSEcCtD
Alprostadil—Loss of consciousness—Epirubicin—ovarian cancer	0.000367	0.000751	CcSEcCtD
Alprostadil—Cough—Epirubicin—ovarian cancer	0.000365	0.000746	CcSEcCtD
Alprostadil—Asthenia—Docetaxel—ovarian cancer	0.000363	0.000742	CcSEcCtD
Alprostadil—Convulsion—Epirubicin—ovarian cancer	0.000362	0.000741	CcSEcCtD
Alprostadil—Hypertension—Epirubicin—ovarian cancer	0.000361	0.000738	CcSEcCtD
Alprostadil—Pruritus—Docetaxel—ovarian cancer	0.000358	0.000732	CcSEcCtD
Alprostadil—Anaemia—Doxorubicin—ovarian cancer	0.000357	0.000731	CcSEcCtD
Alprostadil—Nausea—Paclitaxel—ovarian cancer	0.000354	0.000725	CcSEcCtD
Alprostadil—Discomfort—Epirubicin—ovarian cancer	0.000352	0.000719	CcSEcCtD
Alprostadil—Dry mouth—Epirubicin—ovarian cancer	0.000348	0.000712	CcSEcCtD
Alprostadil—Syncope—Doxorubicin—ovarian cancer	0.000347	0.000709	CcSEcCtD
Alprostadil—Diarrhoea—Docetaxel—ovarian cancer	0.000346	0.000708	CcSEcCtD
Alprostadil—Oedema—Epirubicin—ovarian cancer	0.000341	0.000698	CcSEcCtD
Alprostadil—Loss of consciousness—Doxorubicin—ovarian cancer	0.00034	0.000695	CcSEcCtD
Alprostadil—Infection—Epirubicin—ovarian cancer	0.000339	0.000693	CcSEcCtD
Alprostadil—Cough—Doxorubicin—ovarian cancer	0.000338	0.00069	CcSEcCtD
Alprostadil—Shock—Epirubicin—ovarian cancer	0.000336	0.000686	CcSEcCtD
Alprostadil—Convulsion—Doxorubicin—ovarian cancer	0.000335	0.000685	CcSEcCtD
Alprostadil—Dizziness—Docetaxel—ovarian cancer	0.000334	0.000684	CcSEcCtD
Alprostadil—Thrombocytopenia—Epirubicin—ovarian cancer	0.000334	0.000683	CcSEcCtD
Alprostadil—Hypertension—Doxorubicin—ovarian cancer	0.000334	0.000683	CcSEcCtD
Alprostadil—Tachycardia—Epirubicin—ovarian cancer	0.000333	0.000681	CcSEcCtD
Alprostadil—Skin disorder—Epirubicin—ovarian cancer	0.000331	0.000678	CcSEcCtD
Alprostadil—Hyperhidrosis—Epirubicin—ovarian cancer	0.00033	0.000674	CcSEcCtD
Alprostadil—Discomfort—Doxorubicin—ovarian cancer	0.000325	0.000665	CcSEcCtD
Alprostadil—Dry mouth—Doxorubicin—ovarian cancer	0.000322	0.000658	CcSEcCtD
Alprostadil—Rash—Docetaxel—ovarian cancer	0.000319	0.000652	CcSEcCtD
Alprostadil—Hypotension—Epirubicin—ovarian cancer	0.000319	0.000652	CcSEcCtD
Alprostadil—Dermatitis—Docetaxel—ovarian cancer	0.000319	0.000651	CcSEcCtD
Alprostadil—Headache—Docetaxel—ovarian cancer	0.000317	0.000648	CcSEcCtD
Alprostadil—Oedema—Doxorubicin—ovarian cancer	0.000316	0.000645	CcSEcCtD
Alprostadil—Infection—Doxorubicin—ovarian cancer	0.000314	0.000641	CcSEcCtD
Alprostadil—Shock—Doxorubicin—ovarian cancer	0.000311	0.000635	CcSEcCtD
Alprostadil—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000309	0.000632	CcSEcCtD
Alprostadil—Tachycardia—Doxorubicin—ovarian cancer	0.000308	0.00063	CcSEcCtD
Alprostadil—Skin disorder—Doxorubicin—ovarian cancer	0.000307	0.000627	CcSEcCtD
Alprostadil—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000305	0.000624	CcSEcCtD
Alprostadil—Nausea—Docetaxel—ovarian cancer	0.0003	0.000614	CcSEcCtD
Alprostadil—Dyspepsia—Epirubicin—ovarian cancer	0.0003	0.000614	CcSEcCtD
Alprostadil—Hypotension—Doxorubicin—ovarian cancer	0.000295	0.000603	CcSEcCtD
Alprostadil—Pain—Epirubicin—ovarian cancer	0.000292	0.000596	CcSEcCtD
Alprostadil—Feeling abnormal—Epirubicin—ovarian cancer	0.000281	0.000575	CcSEcCtD
Alprostadil—Dyspepsia—Doxorubicin—ovarian cancer	0.000278	0.000568	CcSEcCtD
Alprostadil—Pain—Doxorubicin—ovarian cancer	0.00027	0.000552	CcSEcCtD
Alprostadil—Abdominal pain—Epirubicin—ovarian cancer	0.00027	0.000551	CcSEcCtD
Alprostadil—Body temperature increased—Epirubicin—ovarian cancer	0.00027	0.000551	CcSEcCtD
Alprostadil—Feeling abnormal—Doxorubicin—ovarian cancer	0.00026	0.000532	CcSEcCtD
Alprostadil—Abdominal pain—Doxorubicin—ovarian cancer	0.00025	0.00051	CcSEcCtD
Alprostadil—Body temperature increased—Doxorubicin—ovarian cancer	0.00025	0.00051	CcSEcCtD
Alprostadil—Asthenia—Epirubicin—ovarian cancer	0.000245	0.0005	CcSEcCtD
Alprostadil—Pruritus—Epirubicin—ovarian cancer	0.000241	0.000494	CcSEcCtD
Alprostadil—Diarrhoea—Epirubicin—ovarian cancer	0.000233	0.000477	CcSEcCtD
Alprostadil—Asthenia—Doxorubicin—ovarian cancer	0.000226	0.000463	CcSEcCtD
Alprostadil—Dizziness—Epirubicin—ovarian cancer	0.000226	0.000461	CcSEcCtD
Alprostadil—Pruritus—Doxorubicin—ovarian cancer	0.000223	0.000457	CcSEcCtD
Alprostadil—Diarrhoea—Doxorubicin—ovarian cancer	0.000216	0.000442	CcSEcCtD
Alprostadil—Rash—Epirubicin—ovarian cancer	0.000215	0.00044	CcSEcCtD
Alprostadil—Dermatitis—Epirubicin—ovarian cancer	0.000215	0.000439	CcSEcCtD
Alprostadil—Headache—Epirubicin—ovarian cancer	0.000214	0.000437	CcSEcCtD
Alprostadil—Dizziness—Doxorubicin—ovarian cancer	0.000209	0.000427	CcSEcCtD
Alprostadil—Nausea—Epirubicin—ovarian cancer	0.000203	0.000414	CcSEcCtD
Alprostadil—Rash—Doxorubicin—ovarian cancer	0.000199	0.000407	CcSEcCtD
Alprostadil—Dermatitis—Doxorubicin—ovarian cancer	0.000199	0.000407	CcSEcCtD
Alprostadil—Headache—Doxorubicin—ovarian cancer	0.000198	0.000404	CcSEcCtD
Alprostadil—Nausea—Doxorubicin—ovarian cancer	0.000188	0.000383	CcSEcCtD
Alprostadil—PTGER1—Signaling by GPCR—PPP2R1A—ovarian cancer	0.000182	0.00106	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	0.000182	0.00106	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CG—ovarian cancer	0.000181	0.00105	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—CXCL8—ovarian cancer	0.000175	0.00102	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CXCL8—ovarian cancer	0.000175	0.00102	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PIK3CD—ovarian cancer	0.000175	0.00102	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	0.000174	0.00102	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—IL2—ovarian cancer	0.000173	0.00101	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—YAP1—ovarian cancer	0.000168	0.000981	CbGpPWpGaD
Alprostadil—ABCC5—Disease—FASN—ovarian cancer	0.000164	0.000955	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—YAP1—ovarian cancer	0.000164	0.000954	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—YAP1—ovarian cancer	0.000164	0.000954	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PARP1—ovarian cancer	0.000163	0.000951	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PIK3CB—ovarian cancer	0.000163	0.00095	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—XIAP—ovarian cancer	0.00016	0.000934	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—XIAP—ovarian cancer	0.00016	0.000934	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PPP2R1A—ovarian cancer	0.000159	0.00093	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CD—ovarian cancer	0.000159	0.000926	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SMARCA4—ovarian cancer	0.000156	0.000911	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SMARCA4—ovarian cancer	0.000156	0.000911	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SLC2A1—ovarian cancer	0.000156	0.000907	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PIK3CB—ovarian cancer	0.000152	0.000889	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EREG—ovarian cancer	0.000152	0.000889	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EREG—ovarian cancer	0.000152	0.000889	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ABCB1—ovarian cancer	0.000152	0.000887	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—IL2—ovarian cancer	0.00015	0.000873	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	0.000147	0.000857	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—CXCL8—ovarian cancer	0.000146	0.000854	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PGR—ovarian cancer	0.000143	0.000833	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PGR—ovarian cancer	0.000143	0.000833	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—IL2—ovarian cancer	0.00014	0.000816	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—CAV1—ovarian cancer	0.000139	0.000811	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	0.000139	0.000811	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CB—ovarian cancer	0.000138	0.000807	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—FASN—ovarian cancer	0.000137	0.0008	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—SLC5A5—ovarian cancer	0.000135	0.000786	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CG—ovarian cancer	0.000134	0.000784	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CG—ovarian cancer	0.000134	0.000784	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CXCL8—ovarian cancer	0.000133	0.000776	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PARP1—ovarian cancer	0.000133	0.000774	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PARP1—ovarian cancer	0.000133	0.000774	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	0.000132	0.000772	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PPP2R1A—ovarian cancer	0.000132	0.000771	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—SLC2A1—ovarian cancer	0.00013	0.00076	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—VEGFA—ovarian cancer	0.000127	0.000742	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL2—ovarian cancer	0.000127	0.000741	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL6ST—ovarian cancer	0.000127	0.000741	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL6ST—ovarian cancer	0.000127	0.000741	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CG—ovarian cancer	0.000127	0.000739	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TERT—ovarian cancer	0.000127	0.000739	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—NRAS—ovarian cancer	0.000126	0.000732	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP1B1—ovarian cancer	0.000125	0.000728	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CG—ovarian cancer	0.000122	0.000712	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CG—ovarian cancer	0.000122	0.000712	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—MAPK3—ovarian cancer	0.00012	0.000701	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CD—ovarian cancer	0.000118	0.000689	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CD—ovarian cancer	0.000118	0.000689	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CAV1—ovarian cancer	0.000117	0.000683	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	0.000115	0.00067	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—MAPK1—ovarian cancer	0.000114	0.000667	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ESR1—ovarian cancer	0.000113	0.000658	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CD—ovarian cancer	0.000111	0.00065	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL6ST—ovarian cancer	0.000111	0.000648	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPP2R1A—ovarian cancer	0.000111	0.000646	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—KRAS—ovarian cancer	0.000108	0.00063	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PPP2R1A—ovarian cancer	0.000108	0.000628	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PPP2R1A—ovarian cancer	0.000108	0.000628	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CD—ovarian cancer	0.000107	0.000626	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CD—ovarian cancer	0.000107	0.000626	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—APC—ovarian cancer	0.000107	0.000622	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CG—ovarian cancer	0.000107	0.000622	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—NRAS—ovarian cancer	0.000107	0.000622	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TERT—ovarian cancer	0.000105	0.000613	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CB—ovarian cancer	0.000103	0.0006	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CB—ovarian cancer	0.000103	0.0006	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ABCB1—ovarian cancer	0.000103	0.0006	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—MAPK3—ovarian cancer	0.000102	0.000596	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—TYMS—ovarian cancer	0.000101	0.000589	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PIK3CA—ovarian cancer	9.93e-05	0.000579	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CXCL8—ovarian cancer	9.89e-05	0.000577	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CXCL8—ovarian cancer	9.89e-05	0.000577	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—MAPK1—ovarian cancer	9.72e-05	0.000567	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—EGFR—ovarian cancer	9.72e-05	0.000567	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CAV1—ovarian cancer	9.72e-05	0.000567	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CB—ovarian cancer	9.71e-05	0.000566	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TP53—ovarian cancer	9.61e-05	0.00056	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—IL2—ovarian cancer	9.45e-05	0.000551	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—IL2—ovarian cancer	9.45e-05	0.000551	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	9.38e-05	0.000547	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CD—ovarian cancer	9.38e-05	0.000547	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CB—ovarian cancer	9.35e-05	0.000545	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CB—ovarian cancer	9.35e-05	0.000545	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PIK3CA—ovarian cancer	9.29e-05	0.000542	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IL6ST—ovarian cancer	9.21e-05	0.000537	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—HRAS—ovarian cancer	9.19e-05	0.000536	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—KRAS—ovarian cancer	9.18e-05	0.000536	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CXCL8—ovarian cancer	8.98e-05	0.000524	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CXCL8—ovarian cancer	8.98e-05	0.000524	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IL2—ovarian cancer	8.92e-05	0.00052	CbGpPWpGaD
Alprostadil—ABCC5—Disease—APC—ovarian cancer	8.85e-05	0.000516	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL2—ovarian cancer	8.58e-05	0.000501	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL2—ovarian cancer	8.58e-05	0.000501	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TERT—ovarian cancer	8.55e-05	0.000499	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TERT—ovarian cancer	8.55e-05	0.000499	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CA—ovarian cancer	8.44e-05	0.000492	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ERBB2—ovarian cancer	8.28e-05	0.000483	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MTOR—ovarian cancer	8.18e-05	0.000477	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CB—ovarian cancer	8.18e-05	0.000477	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CAV1—ovarian cancer	8.14e-05	0.000475	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—AKT1—ovarian cancer	8.11e-05	0.000473	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CAV1—ovarian cancer	7.91e-05	0.000461	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CAV1—ovarian cancer	7.91e-05	0.000461	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CXCL8—ovarian cancer	7.86e-05	0.000458	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—HRAS—ovarian cancer	7.81e-05	0.000455	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CD—ovarian cancer	7.78e-05	0.000454	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CDKN1B—ovarian cancer	7.67e-05	0.000447	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ESR1—ovarian cancer	7.62e-05	0.000445	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ESR1—ovarian cancer	7.62e-05	0.000445	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AKT1—ovarian cancer	7.59e-05	0.000443	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—VEGFA—ovarian cancer	7.58e-05	0.000442	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CASP3—ovarian cancer	7.52e-05	0.000439	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL2—ovarian cancer	7.51e-05	0.000438	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL6ST—ovarian cancer	7.5e-05	0.000437	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL6ST—ovarian cancer	7.5e-05	0.000437	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NRAS—ovarian cancer	7.48e-05	0.000437	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL6—ovarian cancer	7.47e-05	0.000436	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CG—ovarian cancer	7.41e-05	0.000432	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCND1—ovarian cancer	7.32e-05	0.000427	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CTNNB1—ovarian cancer	7.25e-05	0.000423	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—APC—ovarian cancer	7.21e-05	0.00042	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—APC—ovarian cancer	7.21e-05	0.00042	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CG—ovarian cancer	7.21e-05	0.00042	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CG—ovarian cancer	7.21e-05	0.00042	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—NRAS—ovarian cancer	7.21e-05	0.00042	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—NRAS—ovarian cancer	7.21e-05	0.00042	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—MAPK3—ovarian cancer	7.17e-05	0.000418	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MMP9—ovarian cancer	7.11e-05	0.000414	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTEN—ovarian cancer	7.06e-05	0.000412	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—MAPK3—ovarian cancer	6.9e-05	0.000403	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—MAPK3—ovarian cancer	6.9e-05	0.000403	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AKT1—ovarian cancer	6.89e-05	0.000402	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ERBB2—ovarian cancer	6.87e-05	0.000401	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—MAPK1—ovarian cancer	6.82e-05	0.000398	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CB—ovarian cancer	6.78e-05	0.000396	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MTOR—ovarian cancer	6.78e-05	0.000396	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—MAPK1—ovarian cancer	6.57e-05	0.000383	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—MAPK1—ovarian cancer	6.57e-05	0.000383	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—EGFR—ovarian cancer	6.57e-05	0.000383	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—EGFR—ovarian cancer	6.57e-05	0.000383	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CD—ovarian cancer	6.52e-05	0.00038	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—KRAS—ovarian cancer	6.44e-05	0.000376	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—VEGFA—ovarian cancer	6.38e-05	0.000372	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CDKN1B—ovarian cancer	6.36e-05	0.000371	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CD—ovarian cancer	6.34e-05	0.00037	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CD—ovarian cancer	6.34e-05	0.00037	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—STAT3—ovarian cancer	6.32e-05	0.000368	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NRAS—ovarian cancer	6.3e-05	0.000368	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CA—ovarian cancer	6.28e-05	0.000366	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CA—ovarian cancer	6.28e-05	0.000366	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—KRAS—ovarian cancer	6.2e-05	0.000362	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—KRAS—ovarian cancer	6.2e-05	0.000362	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MAPK3—ovarian cancer	6.04e-05	0.000352	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CTNNB1—ovarian cancer	6.01e-05	0.000351	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CA—ovarian cancer	5.92e-05	0.000345	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MYC—ovarian cancer	5.87e-05	0.000342	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTEN—ovarian cancer	5.86e-05	0.000342	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MAPK1—ovarian cancer	5.74e-05	0.000335	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EGFR—ovarian cancer	5.74e-05	0.000335	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TP53—ovarian cancer	5.73e-05	0.000334	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CA—ovarian cancer	5.7e-05	0.000332	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CA—ovarian cancer	5.7e-05	0.000332	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CB—ovarian cancer	5.68e-05	0.000331	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ERBB2—ovarian cancer	5.6e-05	0.000326	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ERBB2—ovarian cancer	5.6e-05	0.000326	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MTOR—ovarian cancer	5.52e-05	0.000322	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CB—ovarian cancer	5.52e-05	0.000322	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MTOR—ovarian cancer	5.52e-05	0.000322	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CB—ovarian cancer	5.52e-05	0.000322	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—HRAS—ovarian cancer	5.48e-05	0.000319	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KRAS—ovarian cancer	5.42e-05	0.000316	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CXCL8—ovarian cancer	5.31e-05	0.00031	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CXCL8—ovarian cancer	5.31e-05	0.00031	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—HRAS—ovarian cancer	5.27e-05	0.000308	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—HRAS—ovarian cancer	5.27e-05	0.000308	CbGpPWpGaD
Alprostadil—ABCC5—Disease—STAT3—ovarian cancer	5.24e-05	0.000306	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NRAS—ovarian cancer	5.23e-05	0.000305	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CDKN1B—ovarian cancer	5.18e-05	0.000302	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CDKN1B—ovarian cancer	5.18e-05	0.000302	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AKT1—ovarian cancer	5.13e-05	0.000299	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AKT1—ovarian cancer	5.13e-05	0.000299	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CASP3—ovarian cancer	5.08e-05	0.000296	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CASP3—ovarian cancer	5.08e-05	0.000296	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL2—ovarian cancer	5.07e-05	0.000296	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL2—ovarian cancer	5.07e-05	0.000296	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL6—ovarian cancer	5.05e-05	0.000294	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL6—ovarian cancer	5.05e-05	0.000294	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MAPK3—ovarian cancer	5.01e-05	0.000292	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CA—ovarian cancer	4.98e-05	0.000291	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCND1—ovarian cancer	4.94e-05	0.000288	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCND1—ovarian cancer	4.94e-05	0.000288	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTEN—ovarian cancer	4.91e-05	0.000286	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CTNNB1—ovarian cancer	4.9e-05	0.000286	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CTNNB1—ovarian cancer	4.9e-05	0.000286	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MYC—ovarian cancer	4.87e-05	0.000284	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—AKT1—ovarian cancer	4.83e-05	0.000282	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TP53—ovarian cancer	4.82e-05	0.000281	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MMP9—ovarian cancer	4.8e-05	0.00028	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MMP9—ovarian cancer	4.8e-05	0.00028	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTEN—ovarian cancer	4.77e-05	0.000278	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTEN—ovarian cancer	4.77e-05	0.000278	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MAPK1—ovarian cancer	4.76e-05	0.000278	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EGFR—ovarian cancer	4.76e-05	0.000278	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AKT1—ovarian cancer	4.66e-05	0.000272	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AKT1—ovarian cancer	4.66e-05	0.000272	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HRAS—ovarian cancer	4.61e-05	0.000269	CbGpPWpGaD
Alprostadil—ABCC5—Disease—KRAS—ovarian cancer	4.5e-05	0.000262	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL6—ovarian cancer	4.41e-05	0.000257	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—VEGFA—ovarian cancer	4.31e-05	0.000251	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—VEGFA—ovarian cancer	4.31e-05	0.000251	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—STAT3—ovarian cancer	4.27e-05	0.000249	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—STAT3—ovarian cancer	4.27e-05	0.000249	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NRAS—ovarian cancer	4.26e-05	0.000248	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NRAS—ovarian cancer	4.26e-05	0.000248	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CA—ovarian cancer	4.13e-05	0.000241	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAPK3—ovarian cancer	4.08e-05	0.000238	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAPK3—ovarian cancer	4.08e-05	0.000238	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKT1—ovarian cancer	4.07e-05	0.000237	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MYC—ovarian cancer	3.97e-05	0.000231	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MYC—ovarian cancer	3.97e-05	0.000231	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MAPK1—ovarian cancer	3.88e-05	0.000226	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MAPK1—ovarian cancer	3.88e-05	0.000226	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EGFR—ovarian cancer	3.88e-05	0.000226	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EGFR—ovarian cancer	3.88e-05	0.000226	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HRAS—ovarian cancer	3.82e-05	0.000223	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KRAS—ovarian cancer	3.66e-05	0.000214	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KRAS—ovarian cancer	3.66e-05	0.000214	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IL6—ovarian cancer	3.66e-05	0.000214	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CA—ovarian cancer	3.46e-05	0.000202	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKT1—ovarian cancer	3.38e-05	0.000197	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CA—ovarian cancer	3.37e-05	0.000196	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CA—ovarian cancer	3.37e-05	0.000196	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TP53—ovarian cancer	3.26e-05	0.00019	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TP53—ovarian cancer	3.26e-05	0.00019	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HRAS—ovarian cancer	3.11e-05	0.000182	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HRAS—ovarian cancer	3.11e-05	0.000182	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL6—ovarian cancer	2.98e-05	0.000174	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL6—ovarian cancer	2.98e-05	0.000174	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AKT1—ovarian cancer	2.83e-05	0.000165	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKT1—ovarian cancer	2.75e-05	0.00016	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKT1—ovarian cancer	2.75e-05	0.00016	CbGpPWpGaD
